News

Sofwave Medical Achieves Q2 Milestones with Record Revenue

Sofwave Medical Achieves Q2 Milestones with Record Revenue

Sofwave Medical Financial Results Overview

In a remarkable display of growth, Sofwave Medical Ltd, a prominent player in the aesthetics market, has showcased its financial performance for the second quarter and the first half of the fiscal year 2025. The company reported a record revenue of $21 million for the second quarter alone, marking a 43% increase from the previous year, with positive trends in all key financial metrics.

Financial Highlights of Q2

Sofwave's achievements in the second quarter are a testament to its robust business model and dedication to innovation in non-invasive medical devices. Achieving an impressive gross margin of 75.5%, the company's financials reflect a strong profitability trajectory. Cash generation was notably positive as well, with $3.6 million generated in the second quarter.

Steady Growth in Recurring Revenue

The second quarter also saw a substantial leap in recurring revenue, which reached $9.2 million, reflecting a year-over-year growth of 53%. This component constitutes about 44% of the total revenue, signaling strong customer retention and satisfaction with Sofwave's technological offerings.

Performance of the First Half

Across the first half of 2025, Sofwave Medical garnered a total revenue of $37.6 million, demonstrating a year-over-year increase of 35%. The gross profit for this period was recorded at $28.6 million, with an impressive gross margin remained steady at 75.9%.

Management Insights and Future Outlook

Mr. Louis Scafuri, CEO of Sofwave Medical, expressed confidence in the company’s upward trajectory. He stated that the strong revenue results and profitability reflect the effectiveness of Sofwave's innovative technologies and dedication to providing exceptional return on investment for their medical partners. With over 600,000 treatments conducted since inception, the company is poised to expand further within existing markets.

Innovations Driving Demand

The company’s product lineup, including the SUPERB™ and Pure Impact™ technologies, has become integral to its market appeal. The recent clearance of the SUPERB™ technology in Japan has opened new avenues for growth in the Asia-Pacific region. As more facilities adopt these technologies, Sofwave continues to draw in a larger customer base.

Recent Achievements and Industry Positioning

Sofwave Medical has made substantial inroads in the aesthetics market, showcasing its latest innovations at significant industry events. Recently, the company launched its liftHD body applicator at a renowned medical symposium, further solidifying its reputation as a leader in non-invasive treatments. Currently, the company enjoys over 1 million followers across social media platforms, amplifying its brand reach and influence within the aesthetics industry.

Addressing Market Needs

With a focus on patient satisfaction, Sofwave's treatment modalities are aligning with current industry trends, such as the popularity of GLP-1 inhibitors, driving demand for its unique skin lifting and toning applications. As the industry evolves, Sofwave Medical is committed to maintaining its innovative edge to meet patient and provider needs.

Financial Summary and Health

By June 30, the company reported cash and cash equivalents of $24 million — a growth fueled by disciplined expense management and a keen focus on sustainable profitability. As Sofwave progresses, the emphasis on achieving operational break-even status remains a top priority for management, ensuring long-term financial health and investor confidence.

Frequently Asked Questions

What was Sofwave Medical’s second quarter revenue?

Sofwave Medical reported a revenue of $21 million for the second quarter, representing a 43% year-over-year growth.

How much cash did Sofwave generate in the second quarter?

In the second quarter of 2025, Sofwave Medical generated $3.6 million in cash.

What are the key treatment technologies offered by Sofwave?

Sofwave offers its proprietary SUPERB™ technology for non-invasive skin treatments, in addition to the Pure Impact™ module for muscle toning.

How many treatments has Sofwave completed since its inception?

To date, Sofwave has completed over 600,000 treatments globally.

What is the management's outlook on profitability for Sofwave?

Sofwave's management is optimistic about achieving operating break-even status by the end of fiscal year 2025, emphasizing sustainable growth strategies.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Pinnacol’s Community Work Earns Denver Chamber Recognition

Updated Category News Views 67

A workers’ comp insurer usually becomes visible on somebody’s worst day; Pinnacol Assurance is being recognized for the work it keeps doing around those days. The Denver Metro Chamber of Commerce has given the Colorado-based, member-owned carrier its 2026 Business Impact Award for Corporate Social Responsibility. Awards can be cheap applause, frankly. This one...

Continue Reading
CVRx Lawsuit Puts a Hard Date on Investor Decisions

Updated Category News Views 65

One ugly filing after the bell can vaporize years of shareholder confidence, and CVRx just supplied the painful exhibit. On August 7, 2026, shares of CVRx fell $3.55, or 59.76%, to close at $2.39 after the company disclosed a U.S. Department of Justice civil investigative demand in its August 6 Form 10-Q. That is not a routine bad quarter. It is the sort of disclosure...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 23

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Tigerlily Brings HIV Information to Women’s Health

Updated Category News Views 99

A stubborn information gap is exactly where Tigerlily Foundation is planting its flag. The nonprofit’s new national HIV education and awareness campaign, THE POWER OF U, expands work that began in breast cancer advocacy into another area where women need clear facts, trusted voices, and room to speak without being shamed for needing answers. This is not a story that...

Continue Reading
ASA’s 2026 Grants Push Dermatology Into New Terrain

Updated Category News Views 104

Thirteen Small Bets With Serious Human Stakes Skin science rarely gets the splashy headlines, yet it touches a staggering number of people and carries some very stubborn unanswered questions. American Skin Association’s 2026 grant class puts 13 awards across skin cancer and dermatologic disease, with a noticeable willingness to follow newer clinical terrain rather than...

Continue Reading
Protein Now! Gains Clinician Attention, With Caveats

Updated Category News Views 91

A Small Bottle Has Drawn a Crowd Protein powder tubs have been cluttering kitchens for years; a 3.38-fluid-ounce shot is a cleaner answer to the same daily hassle. NutraBio Labs says more than 800 physicians, nurse practitioners, and physician associates had added PROTEIN NOW! to their individual FrontrowMD patient pages as of November 2026. That earned the product a...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 14

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Africa Tech Festival Puts Trust Ahead of AI Hype Cycle

Updated Category News Views 75

Fifteen thousand people can fill a convention centre, but they cannot magically deliver a package, fund a small business, or repair harm from a bad automated decision. That rather useful dose of reality ran through the final day of Africa Tech Festival 2026 in Cape Town. The 29th edition drew more than 15,000 delegates across three days, and the strongest message was not...

Continue Reading
Epiroc Takes Live Remote Drilling to CES 2027 Stage

Updated Category News Views 48

A drill rig chewing through Virginia rock from a Las Vegas convention booth is either a serious industrial-tech moment or an expensive magic trick. At CES 2027, Epiroc intends to make the distinction painfully clear. From January 6 through 9, the Stockholm-based mining-equipment company and Luck Stone will connect Booth 7031 in the LVCC West Hall to a working quarry in...

Continue Reading
Healthcare's Prevention Puzzle Needs Better Incentives

Updated Category News Views 113

When Savings Belong to the Next Plan A patient changing insurance plans can turn prevention into nobody’s asset. That is the uncomfortable little engine inside Russell Greenfield’s recent argument: an insurer may pay today for a program that helps prevent chronic illness, only to watch the eventual savings land with another plan after the member moves on. The person...

Continue Reading

Top 5 Most Recently Viewed Articles

Beta Glucan Market Set to Exceed USD 31 Billion by 2030

Updated Category News Views 56

Exploring the Growth of the Beta Glucan Market The beta glucan market is experiencing remarkable growth, largely driven by increasing awareness of its health benefits. More and more consumers are recognizing the importance of supporting their immune systems and managing cholesterol levels, which has led to a surge in demand across numerous sectors, including...

Continue Reading
AiPPT.com: Crafting the Next Era of AI-Driven Presentations

Updated Category News Views 177

Transforming Presentations with AiPPT.com In the evolving landscape of digital work, AiPPT.com stands out as a leading provider of AI-native tools that are reshaping the way presentations are crafted. As an advanced AI presentation maker, AiPPT.com is committed to enhancing user experiences by making the process of creating engaging and professional presentations much...

Continue Reading
Acme Mills Launches Natura: Revolutionizing Sustainable Fabrics

Updated Category News Views 244

Revolutionizing Textile Innovation with Natura Acme Mills Company, a recognized pioneer in textile manufacturing, has proudly unveiled its latest innovation, Natura. This new line of bio-based polylactic acid (PLA) fabrics aims to replace traditional petroleum-based materials such as PET, PP, and Nylon. With Natura, Acme Mills is not just promoting a product; it is...

Continue Reading
Class Action Alert for C3.ai, Inc. Investors - Join Now!

Updated Category News Views 123

Opportunity for C3.ai, Inc. Shareholders to Join Class Action Attention, shareholders of C3.ai, Inc. (NYSE: AI). A significant class action suit is currently underway, and your involvement could be crucial. If you purchased shares during the class period, there may be an opportunity for you to participate in a recovery process without the requirement of being a lead...

Continue Reading
EyePoint Pharmaceuticals: Innovations and Financial Insights

Updated Category News Views 224

EyePoint Pharmaceuticals Set to Showcase Q2 Financials EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pioneering company dedicated to developing advanced therapeutics for serious retinal diseases, plans to share its second quarter 2025 financial results. This announcement will be accompanied by a live conference call and webcast on a scheduled day, promising to provide...

Continue Reading